139 related articles for article (PubMed ID: 33666400)
1. The Additional Effect of Individualized Prescriber-Focused Feedback on General Guideline Instruction in Reducing Antipsychotic Polypharmacy in Inpatients.
Lochmann van Bennekom MWH; Gijsman HJ; Groenewoud H; Verkes RJ
J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):129-134. PubMed ID: 33666400
[TBL] [Abstract][Full Text] [Related]
2. Development and delivery of a quality improvement program to reduce antipsychotic polytherapy.
Gören JL; Beck SE; Mills BJ; Shtasel DL; Dufresne RL
J Manag Care Pharm; 2010; 16(6):393-401. PubMed ID: 20635830
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients: The Japan Adverse Drug Events Study.
Ayani N; Morimoto T; Sakuma M; Kikuchi T; Watanabe K; Narumoto J
J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):397-402. PubMed ID: 34108429
[TBL] [Abstract][Full Text] [Related]
4. Improving quality of antipsychotic polypharmacy: a pilot study.
Høilund H; Galea DP; Ringen PA
Nord J Psychiatry; 2020 Apr; 74(3):208-212. PubMed ID: 31724898
[No Abstract] [Full Text] [Related]
5. Maintenance phase treatment of psychotic disorders in outpatients from Serbia - focus on long-term benzodiazepine use.
Marić NP; Andrić Petrović S; Jerotić S; Ristić I; Savić B; Zebić M; Vuković V; Britvić D; Golubović O; Jakšić M; Jevđić K; Kolašinac Z; Lalović N; Mirković Ilić J; Nikolić S; Paunović Č; Pavlović Z; Pejović Nikolić S; Perović V; Popović J; Ranđić Avakumović V; Stojanović S; Tatarević M; Živković I; Voskresenski T; Jovanović N
Int J Psychiatry Clin Pract; 2020 Sep; 24(3):315-321. PubMed ID: 32459564
[No Abstract] [Full Text] [Related]
6. The hidden magnitude of polypharmacy: using defined daily doses and maximum licensed daily doses to measure antipsychotic load.
Nguyen ML; Sunderland B; Lim S; Hattingh L; Chalmers L
Int J Clin Pharm; 2019 Dec; 41(6):1642-1651. PubMed ID: 31677120
[TBL] [Abstract][Full Text] [Related]
7. Ecological Assessment of Clinicians' Antipsychotic Prescription Habits in Psychiatric Inpatients: A Novel Web- and Mobile Phone-Based Prototype for a Dynamic Clinical Decision Support System.
Berrouiguet S; Barrigón ML; Brandt SA; Nitzburg GC; Ovejero S; Alvarez-Garcia R; Carballo J; Walter M; Billot R; Lenca P; Delgado-Gomez D; Ropars J; de la Calle Gonzalez I; Courtet P; Baca-García E
J Med Internet Res; 2017 Jan; 19(1):e25. PubMed ID: 28126703
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.
Armstrong KS; Temmingh H
Braz J Psychiatry; 2017; 39(4):293-301. PubMed ID: 28177063
[TBL] [Abstract][Full Text] [Related]
9. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients.
Paton C; Lelliott P; Harrington M; Okocha C; Sensky T; Duffett R
J Psychopharmacol; 2003 Jun; 17(2):223-9. PubMed ID: 12870571
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.
Correll CU; Gallego JA
Psychiatr Clin North Am; 2012 Sep; 35(3):661-81. PubMed ID: 22929872
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the combination of feedback and educational recommendations for improving drug prescription in general practice.
Madridejos-Mora R; Amado-Guirado E; Pérez-Rodríguez MT
Med Care; 2004 Jul; 42(7):643-8. PubMed ID: 15213488
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.
Ayenew W; Asmamaw G; Bitew T
Int J Neuropsychopharmacol; 2021 Dec; 24(12):956-964. PubMed ID: 34245271
[TBL] [Abstract][Full Text] [Related]
13. Use of Academic Detailing With Audit and Feedback to Improve Antipsychotic Pharmacotherapy.
Brunette MF; Cotes RO; de Nesnera A; McHugo G; Dzebisashvili N; Xie H; Bartels SJ
Psychiatr Serv; 2018 Sep; 69(9):1021-1028. PubMed ID: 29879874
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic Polypharmacy and High-Dose Antipsychotics in Involuntary Patients: a Seven-Year Audit of Discharge Prescriptions in an Acute Care Unit.
Martinho S; Poças A; Simões M; Laureano C
Psychiatr Q; 2021 Mar; 92(1):1-14. PubMed ID: 32430698
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service.
John AP; Gee T; Alexander S; Ramankutty P; Dragovic M
Australas Psychiatry; 2014 Dec; 22(6):546-50. PubMed ID: 25147317
[TBL] [Abstract][Full Text] [Related]
17. Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process.
Kadra G; Stewart R; Shetty H; Jackson RG; Greenwood MA; Roberts A; Chang CK; MacCabe JH; Hayes RD
BMC Psychiatry; 2015 Jul; 15():166. PubMed ID: 26198696
[TBL] [Abstract][Full Text] [Related]
18. Use of medication algorithms in first episode psychosis: a naturalistic observational study.
Yeisen RA; Joa I; Johannessen JO; Opjordsmoen S
Early Interv Psychiatry; 2016 Dec; 10(6):503-510. PubMed ID: 25588989
[TBL] [Abstract][Full Text] [Related]
19. Dosage patterns of antipsychotic drugs for the treatment of schizophrenia in Swedish ambulatory clinical practice--a highly individualized therapy.
Bingefors K; Isacson D; Lindström E
Nord J Psychiatry; 2003; 57(4):263-9. PubMed ID: 12888400
[TBL] [Abstract][Full Text] [Related]
20. Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong.
Hung GB; Cheung HK
Hong Kong Med J; 2008 Feb; 14(1):35-9. PubMed ID: 18239241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
